Syndax publishes SAVE trial data on Revuforj combination therapy in AML
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl
June 11, 2026 7:00 AM EDTHigh response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42)
Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients
Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders
Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant
Encouraging durability with median overall survival after transplant not reached Â
Combination was generally well-tolerated
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Syndax... More
